This list is an analysis based on recent market events. It's not an investment recommendation.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Show more...
FAQ
What is COSCIENS Biopharma stock price today?▼
The current price of ET80.MU is €4.81 EUR — it has decreased by -1.43% in the past 24 hours. Watch COSCIENS Biopharma stock price performance more closely on the chart.
What is COSCIENS Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange COSCIENS Biopharma stocks are traded under the ticker ET80.MU.
What is COSCIENS Biopharma market cap?▼
Today COSCIENS Biopharma has the market capitalization of 15.32M
When is the next COSCIENS Biopharma earnings date?▼
COSCIENS Biopharma is going to release the next earnings report on August 13, 2026.
What is COSCIENS Biopharma revenue for the last year?▼
COSCIENS Biopharma revenue for the last year amounts to 6.5M EUR.
What is COSCIENS Biopharma net income for the last year?▼
ET80.MU net income for the last year is -9.09M EUR.
In which sector is COSCIENS Biopharma located?▼
COSCIENS Biopharma operates in the Other sector.
When did COSCIENS Biopharma complete a stock split?▼
The last stock split for COSCIENS Biopharma was on July 07, 2026 with a ratio of 50:1.